| 词条 | Indometacin |
| 释义 |
| Watchedfields = changed | verifiedrevid = 460769466 | IUPAC_name = 2- | image = Indometacin.svg | image2 = Indometacin-from-xtal-2003-ball-and-stick.png | pronounce = {{IPAc-en|ɪ|n|d|oʊ-|ˈ|m|ɛ|t|ə|s|ᵻ|n}} | width = 225 | USAN = Indomethacin | tradename = Indocid, Indocin | licence_US = Indomethacin | Drugs.com = {{drugs.com|monograph|indomethacin}} | pregnancy_AU = C | pregnancy_category = C/D (US) | legal_AU = Schedule 4 | legal_CA = Rx-only | legal_UK = POM | legal_US = Rx-only | routes_of_administration = Oral, rectal, IV, topical | bioavailability = ~100% (oral), 80–90% (rectal) | protein_bound = 99%[1] | metabolism = Hepatic | elimination_half-life = 2.6-11.2 hours (adults), 12-28 hours (infants)[1] | excretion = Renal (60%), fecal (33%) | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = 53-86-1 | ATC_prefix = C01 | ATC_suffix = EB03 | ATC_supplemental = {{ATC|M01|AB01}}, {{ATC|M02|AA23}}, {{ATC|S01|BC01}} | PubChem = 3715 | IUPHAR_ligand = 1909 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = DB00328 | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 3584 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = XXE1CET956 | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D00141 | ChEBI_Ref = {{ebicite|correct|EBI}} | ChEBI = 49662 | ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL = 6 | PDB_ligand = IMN | C=19 | H=16 | Cl=1 | N=1 | O=4 | molecular_weight = 357.787 g.mol−1 | SMILES = Cc1c(c2cc(ccc2n1C(=O)c3ccc(cc3)Cl)OC)CC(=O)O | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23) | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = CGIGDMFJXJATDK-UHFFFAOYSA-N }}Indometacin, also known as indomethacin, is a nonsteroidal anti-inflammatory drug (NSAID) commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling from inflammation. It works by inhibiting the production of prostaglandins, endogenous signaling molecules known to cause these symptoms. It does this by inhibiting cyclooxygenase, an enzyme that catalyzes the production of prostaglandins.[1][2] It was patented in 1961 and approved for medical use in 1963.[3] It is marketed under more than twelve different trade names.[4] As of 2015 the cost for a typical month of medication in the United States is less than 25 USD.[5] Medical usesAs an NSAID, indometacin is an analgesic, anti-inflammatory, and antipyretic. Clinical indications for indometacin include:
Indometacin has also been used clinically to delay premature labor, reduce amniotic fluid in polyhydramnios, and to close patent ductus arteriosus. Indometacin is a potent drug with many serious side effects and should not be considered an analgesic for minor aches and pains or fever. The medication is better described as an anti-inflammatory, rather than an analgesic. Indometacin can also affect warfarin and subsequently raise INR. Contraindications
Adverse effects{{see also|Nonsteroidal anti-inflammatory drug}}In general, adverse effects seen with indometacin are similar to all other NSAIDs. For instance, indometacin inhibits both cyclooxygenase-1 and cyclooxygenase-2, which then inhibits the production of prostaglandins in the stomach and intestines responsible for maintaining the mucous lining of the gastrointestinal tract. Indometacin, therefore, like other non-selective COX inhibitors can cause peptic ulcers. These ulcers can result in serious bleeding and/or perforation requiring hospitalization of the patient. To reduce the possibility of peptic ulcers, indometacin should be prescribed at the lowest dosage needed to achieve a therapeutic effect, usually between 50–200 mg/day. It should always be taken with food. Nearly all patients benefit from an ulcer protective drug (e.g. highly dosed antacids, ranitidine 150 mg at bedtime, or omeprazole 20 mg at bedtime). Other common gastrointestinal complaints, including dyspepsia, heartburn and mild diarrhea are less serious and rarely require discontinuation of indometacin. Many NSAIDs, but particularly indometacin, cause lithium retention by reducing its excretion by the kidneys. Thus indometacin users have an elevated risk of lithium toxicity. For patients taking lithium (e.g. for treatment of depression or bipolar disorder), less toxic NSAIDs such as sulindac or aspirin are preferred. All NSAIDs, including indometacin, also increase plasma renin activity and aldosterone levels, and increase sodium and potassium retention. Vasopressin activity is also enhanced. Together these may lead to:
Elevations of serum creatinine and more serious renal damage such as acute renal failure, chronic nephritis and nephrotic syndrome, are also possible. These conditions also often begin with edema and hyperkalemia. Paradoxically yet uncommonly, indometacin can cause headache (10 to 20%), sometimes with vertigo and dizziness, hearing loss, tinnitus, blurred vision (with or without retinal damage). There are unsubstantiated reports of worsening Parkinson's disease, epilepsy, and psychiatric disorders. Cases of life-threatening shock (including angioedema, sweating, severe hypotension and tachycardia as well as acute bronchospasm), severe or lethal hepatitis and severe bone marrow damage have all been reported. Skin reactions and photosensitivity are also possible side effects. The frequency and severity of side effects and the availability of better tolerated alternatives make indometacin today a drug of second choice. Its use in acute gout attacks and in dysmenorrhea is well-established because in these indications the duration of treatment is limited to a few days only, therefore serious side effects are not likely to occur. People should undergo regular physical examination to detect edema and signs of central nervous side effects. Blood pressure checks will reveal development of hypertension. Periodic serum electrolyte (sodium, potassium, chloride) measurements, complete blood cell counts and assessment of liver enzymes as well as of creatinine (renal function) should be performed. This is particularly important if Indometacin is given together with an ACE inhibitor or with potassium-sparing diuretics, because these combinations can lead to hyperkalemia and/or serious kidney failure. No examinations are necessary if only the topical preparations (spray or gel) are applied. Rare cases have shown that use of this medication by pregnant women can have an effect on the fetal heart, possibly resulting in fetal death via premature closing of the Ductus arteriosus.[11] ToxicityIndometacin has a high acute toxicity both for animals (in rats, 12 mg/kg) and for humans. Exact human data does not exist, but some fatal human cases, particularly in children and adolescents, have been seen. Generally, overdose in humans causes drowsiness, dizziness, severe headache, mental confusion, paresthesia, numbness of limbs, nausea and vomiting. Severe gastrointestinal bleeding is also possible. Cerebral edema, and cardiac arrest with fatal outcome have been seen in children. The treatment is symptomatic and largely the same as with diclofenac. However, the possibility of severe GI tract symptoms should be particularly noted. The risk of overdose after exaggerated local treatment with gel or spray is very limited. Mechanism of action{{Main|Non-steroidal anti-inflammatory drug}}Indometacin, a non-steroidal anti-inflammatory drug (NSAID), has similar mode of action when compared to other drugs in this group. Indometacin is a nonselective inhibitor of cyclooxygenase (COX) 1 and 2, the enzymes that participate in prostaglandin synthesis from arachidonic acid. Prostaglandins are hormone-like molecules normally found in the body, where they have a wide variety of effects, some of which lead to pain, fever, and inflammation. By inhibiting the synthesis of prostaglandins, indometacin can reduce pain, fever, and inflammation.[6] Besides, indometacin has logarithmic acid dissociation constant pKa of 3 to 4.5. Since the physiologic body pH is well above the pKa range of indometacin, most of the indometacin molecules will be dissociated into ionised form, leaving very little unionised form of indometacin to cross a cell membrane. If the pH gradient across a cell membrane is high, most of the indometacin molecules will be trapped in one side of the membrane with higher pH. This phenomenon is called "ion trapping". The phenomenon of ion trapping is particularly prominent in the stomach as pH at the stomach mucosa layer is extremely acidic, while the parietal cells are more alkaline. Therefore, indometacin are trapped inside the parietal cells in ionised form, damaging the stomach cells, causing stomach irritation. This stomach irritation can reduce if the stomach acid pH is reduced.[6] Indometacin's role in treating certain headaches is unique compared to other NSAIDs. In addition to the class effect of COX inhibition, there is evidence that indometacin has the ability to reduce cerebral blood flow not only through modulation of nitric oxide pathways but also via intracranial precapillary vasoconstriction.[12] Indometacin property of reducing cerebral blood flow is useful in treating raised intracranial pressure. A case report has shown that an intravenous bolus dose of indometacin given with 2 hours of continuous infusion is able to reduce intracranial pressure by 37% in 10 to 15 minutes and increases cerebral perfusion pressure by 30% at the same time.[6] This reduction in cerebral pressure may be responsible for the remarkable efficacy in a group of headaches that is referred to as "indometacin-responsive headaches", such as idiopathic stabbing headache, chronic paroxysmal hemicranial, and exertional headaches.[13] On the other hand, the activation of superior salivary nucleus in the brainstem is used to stimulate the trigeminal autonomic reflex arc, causing a type of headache called trigeminal autonomic cephalgia. Indometacin inhibits the superior salivatory nucleus, thus relieving this type of headache.[6] Prostaglandins also cause uterine contractions in pregnant women. Indometacin is an effective tocolytic agent,[14] able to delay premature labor by reducing uterine contractions through inhibition of prostaglandin synthesis in the uterus and possibly through calcium channel blockade. Indometacin readily crosses the placenta and can reduce fetal urine production to treat polyhydramnios. It does so by reducing renal blood flow and increasing renal vascular resistance, possibly by enhancing the effects of vasopressin on the fetal kidneys. Other modes of action for indometacin are:
HistoryIndometacin was created in 1963[16] and it was first approved for use in the U.S. by the Food and Drug Administration in 1965. Its mechanism of action, along with several other NSAIDs that inhibit COX, was described in 1971.[17] Society and cultureGeneric namesIndometacin is the {{abbrlink|INN|International Nonproprietary Name}}, {{abbrlink|BAN|British Approved Name}}, and {{abbrlink|JAN|Japanese Accepted Name}} of the drug while indomethacin is the {{abbrlink|USAN|United States Approved Name}}, and former {{abbrlink|AAN|Australian Approved Name}} and {{abbrlink|BAN|British Approved Name}}.[18][19][20]See also
References1. ^1 2 {{cite web|title=Indometacin|work=Martindale: The Complete Drug Reference|publisher=Pharmaceutical Press|date=14 January 2014|access-date=22 June 2014|url=http://www.medicinescomplete.com/mc/martindale/current/ms-2658-m.htm|editor=Brayfield, A|location=London, UK}} 2. ^{{cite document | title=TGA Approved Terminology for Medicines, Section 1 – Chemical Substances | date=July 1999 | publisher=Therapeutic Goods Administration, Department of Health and Ageing, Australian Government | page=70 | url=http://www.tga.gov.au/pdf/medicines-approved-terminology-chemical.pdf | format=PDF }} 3. ^{{cite book |last1=Fischer |first1=Jnos |last2=Ganellin |first2=C. Robin |title=Analogue-based Drug Discovery |date=2006 |publisher=John Wiley & Sons |isbn=9783527607495 |page=517 |url=https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA517 |language=en}} 4. ^Trade names are listed on DrugBank.ca entry DB00328 5. ^{{cite book|last1=Hamilton|first1=Richart|title=Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition|date=2015|publisher=Jones & Bartlett Learning|isbn=9781284057560|page=8}} 6. ^1 2 3 4 5 6 7 8 {{cite journal|last1=Lucas|first1=S|title=The pharmacology of indomethacin|journal=Headache|date=February 2016|volume=56|issue=2|pages=436–446|doi=10.1111/head.12769|pmid=26865183}} 7. ^1 2 3 4 5 6 7 8 9 10 {{cite journal|last1=Dodick|first1=DW|title=Indomethacin-responsive Headache Syndromes|journal=Current Pain and Headache Reports|date=February 2004|volume=8|issue=1|pages=19–26|pmid=14731379}} 8. ^{{cite journal|last1=K C|first1=Sekar|last2=K E|first2=Corff|title=Treatment of patent ductus arteriosus: indomethacin or ibuprofen?|journal=Journal of Perinatology|date=30 April 2008|pages=60–62|doi=10.1038/jp.2008.52|pmid=18446180}} 9. ^{{cite web|last=|first=|title=INDOMETHACIN|url=http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+53-86-1|work=Hazardous Substances Data Bank (HSDB)|publisher=National Library of Medicine's TOXNET|access-date=April 4, 2013}} 10. ^{{cite journal | vauthors = Akbarpour F, Afrasiabi A, Vaziri ND | title = Severe hyperkalemia caused by indomethacin and potassium supplementation | journal = Southern Medical Journal | volume = 78 | issue = 6 | pages = 756–7 | date = June 1985 | pmid = 4002013 | doi = 10.1097/00007611-198506000-00039 }} 11. ^{{cite journal | vauthors = Enzensberger C, Wienhard J, Weichert J, Kawecki A, Degenhardt J, Vogel M, Axt-Fliedner R | title = Idiopathic constriction of the fetal ductus arteriosus: three cases and review of the literature | journal = Journal of Ultrasound in Medicine | volume = 31 | issue = 8 | pages = 1285–91 | date = August 2012 | pmid = 22837295 | url = http://www.jultrasoundmed.org/content/31/8/1285 }}{{dead link|date=December 2017 |bot=InternetArchiveBot |fix-attempted=yes }} 12. ^AE Castellano, G Micieli, P Bellantonio, MG Buzzi, S Marcheselli, F Pompeo, F Rossi, G Nappi. Indometacin Increases the Effect of Isosorbide Dinitrate on Cerebral Hemodynamic in Migraine Patients: Pathogenetic and Therapeutic Implications 13. ^John A. Yagiela, Frank J. Dowd, Bart Johnson, Angelo Mariotti, Enid A. Neidle. Pharmacology and Therapeutics for Dentistry. Chapter 23, Drugs for Treating Orofacial Pain Syndromes. 384-385 14. ^{{cite journal | vauthors = Giles W, Bisits A | title = Preterm labour. The present and future of tocolysis | journal = Best Practice & Research. Clinical Obstetrics & Gynaecology | volume = 21 | issue = 5 | pages = 857–68 | date = October 2007 | pmid = 17459777 | doi = 10.1016/j.bpobgyn.2007.03.011 }} 15. ^Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein. Michael P. Draper, R. L. Martell, Stuart B. LevyPublished in British Journal of Cancer 1997 DOI:10.1038/bjc.1997.145 16. ^{{cite journal | vauthors = Hart FD, Boardman PL | title = Indomethacin: A New Non-steroid Anti-inflammatory Agent | journal = British Medical Journal | volume = 2 | issue = 5363 | pages = 965–70 | date = October 1963 | pmid = 14056924 | pmc = 1873102 | doi = 10.1136/bmj.2.5363.965 }} 17. ^{{cite journal | vauthors = Ferreira SH, Moncada S, Vane JR | title = Indomethacin and aspirin abolish prostaglandin release from the spleen | journal = Nature | volume = 231 | issue = 25 | pages = 237–9 | date = June 1971 | pmid = 5284362 | doi = 10.1038/newbio231237a0 }} 18. ^{{cite book | vauthors = Elks J |title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA684|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=684–}} 19. ^{{cite book|title=Index Nominum 2000: International Drug Directory|url=https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA550|year=2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1|pages=550–}} 20. ^{{cite book|author1=I.K. Morton|author2=Judith M. Hall|title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA153|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-011-4439-1|pages=153–}} External links
9 : 3α-Hydroxysteroid dehydrogenase inhibitors|Antigout agents|Carboxamides|Chloroarenes|Hepatotoxins|Indoles|Nonsteroidal anti-inflammatory drugs|Phenol ethers|Tocolytics |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。